Article Text

Download PDFPDF
Chlamydia trachomatis variant not detected by plasmid based nucleic acid amplification tests: molecular characterisation and failure of single dose azithromycin
  1. Jose Paolo V Magbanua1,
  2. Beng Tin Goh2,
  3. Claude-Edouard Michel1,
  4. Aura Aguirre-Andreasen3,
  5. Sarah Alexander4,
  6. Ines Ushiro-Lumb5,
  7. Catherine Ison4,
  8. Helen Lee1
  1. 1Department of Haematology, University of Cambridge, Cambridge CB2 2PT, UK
  2. 2Ambrose King Centre, Royal London Hospital, Whitechapel, London E1 1BB, UK
  3. 3Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
  4. 4Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency Centre for Infections, London NW9 5HT, UK
  5. 5Virology Department, Royal London Hospital, Whitechapel, London E1 2ES, UK
  1. Correspondence to:
 Helen Lee
 Department of Haematology, University of Cambridge, EABC Site, Long Road, Cambridge CB2 2PT, UK; hl207{at}cam.ac.uk

Footnotes

  • Funding: The study was funded by a grant from the Wellcome Trust, which had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The corresponding author has full access to the data of the study and had final responsibility for the decision to submit for publication.

  • Competing interests: The authors from the University of Cambridge are equity holders of a spin-off company, Diagnostics for the Real World (DRW) Ltd, that was founded to take advantage of rapid test technologies developed at the University of Cambridge. Both the University of Cambridge and the Wellcome Trust are also equity holders of DRW. Other authors declare no competing interests.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding: The study was funded by a grant from the Wellcome Trust, which had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The corresponding author has full access to the data of the study and had final responsibility for the decision to submit for publication.

  • Competing interests: The authors from the University of Cambridge are equity holders of a spin-off company, Diagnostics for the Real World (DRW) Ltd, that was founded to take advantage of rapid test technologies developed at the University of Cambridge. Both the University of Cambridge and the Wellcome Trust are also equity holders of DRW. Other authors declare no competing interests.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editorial
    Nicola Low Helen Ward